Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population

OBJECTIVE: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez‐Diaz, Eva, Perez‐Vicente, Jose A., Villaverde‐Gonzalez, Ramon, Berenguer‐Ruiz, Leticia, Candeliere Merlicco, Antonio, Martinez‐Navarro, Maria Luisa, Gracia Gil, Julia, Romero‐Sanchez, Carlos M., Alfaro‐Saez, Arantxa, Diaz, Inmaculada, Gimenez‐Martinez, Juana, Mendez‐Miralles, Maria Angeles, Millan‐Pascual, Jorge, Jimenez‐Pancho, Javier, Mola, Santiago, Sempere, Angel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886031/
https://www.ncbi.nlm.nih.gov/pubmed/33369288
http://dx.doi.org/10.1002/acn3.51282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886031/
https://www.ncbi.nlm.nih.gov/pubmed/33369288
http://dx.doi.org/10.1002/acn3.51282

Ejemplares similares